Literature DB >> 24648883

Current advances in animal model of chondrosarcoma and related research.

Yu-Xin Liao1, Ying-Qi Hua1, Zheng-Dong Cai2.   

Abstract

Chondrosarcoma is a type of malignant cartilage tumor with a high local recurrence. Due to its resistance to chemo- and radiotherapy, current treatment is limited to surgical resection. Animal model is one of the most important approaches to studying this disease, although systematic reporting on its development is rare. In this review, we summarized the elements involving animal model establishment. On the basis of these elements, we further classified chondrosarcoma animal models into various types. In addition, we compared various measurements for evaluating the animal model. Finally, its specific applications were discussed.

Entities:  

Keywords:  allograft; animal model; chondrosarcoma; heterotopic; orthotopic; xenograft

Year:  2012        PMID: 24648883      PMCID: PMC3956875          DOI: 10.3892/br.2012.13

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  27 in total

Review 1.  In vivo bioluminescence imaging for integrated studies of infection.

Authors:  Timothy C Doyle; Stacy M Burns; Christopher H Contag
Journal:  Cell Microbiol       Date:  2004-04       Impact factor: 3.715

2.  Serum cartilage-derived retinoic acid-sensitive protein (CD-RAP) levels in swarm rat chondrosarcoma.

Authors:  Masahiro Yonekawa; Seiji Kondo; Hideshi Sugiura; Kenji Kobayashi; Tsuyoshi Watanabe; Koji Kimata; L J Sandell; Hisashi Iwata
Journal:  J Orthop Res       Date:  2002-03       Impact factor: 3.494

3.  Paclitaxel-eluting polymer film reduces locoregional recurrence and improves survival in a recurrent sarcoma model: a novel investigational therapy.

Authors:  Rong Liu; Jesse B Wolinsky; Paul J Catalano; Lucian R Chirieac; Andrew J Wagner; Mark W Grinstaff; Yolonda L Colson; Chandrajit P Raut
Journal:  Ann Surg Oncol       Date:  2011-07-16       Impact factor: 5.344

4.  Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.

Authors:  François Gouin; Benjamin Ory; François Rédini; Dominique Heymann
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

5.  The novel benzimidazole derivative, MPTB, induces cell apoptosis in human chondrosarcoma cells.

Authors:  Te-Mao Li; Tsang-Yu Lin; Sheng-Feng Hsu; Chi-Ming Wu; Yi-Chang Su; Shung-Te Kao; Chih-Shiang Chang; Yi-Chin Fong; Chih-Hsin Tang
Journal:  Mol Carcinog       Date:  2011-03-03       Impact factor: 4.784

6.  Chondrosarcoma of bone: an oncological and functional follow-up study.

Authors:  J Bruns; M Elbracht; O Niggemeyer
Journal:  Ann Oncol       Date:  2001-06       Impact factor: 32.976

7.  Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma.

Authors:  E Grimaud; C Damiens; A V Rousselle; N Passuti; D Heymann; F Gouin
Journal:  Histol Histopathol       Date:  2002-10       Impact factor: 2.303

8.  Different growth rates of swarm chondrosarcoma in Lewis and Wistar rats correlate with different thyroid hormone levels.

Authors:  R M Mason; M K Bansal
Journal:  Connect Tissue Res       Date:  1987       Impact factor: 3.417

Review 9.  The clinical approach towards chondrosarcoma.

Authors:  Hans Gelderblom; Pancras C W Hogendoorn; Sander D Dijkstra; Carla S van Rijswijk; Augustinus D Krol; Antonie H M Taminiau; Judith V M G Bovée
Journal:  Oncologist       Date:  2008-03

10.  Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.

Authors:  Frank M Klenke; Amir Abdollahi; Elisabeth Bertl; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell
Journal:  BMC Cancer       Date:  2007-03-17       Impact factor: 4.430

View more
  1 in total

1.  Description of the immune microenvironment of chondrosarcoma and contribution to progression.

Authors:  François A Simard; Iseulys Richert; Alexandra Vandermoeten; Anne-Valérie Decouvelaere; Jean-Philippe Michot; Christophe Caux; Jean-Yves Blay; Aurélie Dutour
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.